Drug Target Review – Issue #3 2017

Posted: 6 September 2017 | | No comments yet

Included in this issue: The importance of industry partnerships; Calcilytics as potential novel therapeutic treatments to halt Alzheimer’s disease; Accelerating neuroscience research with flow cytometry…

Drug Target Review issue 3 2017
  • Foreword: The importance of industry partnerships
    Chris Watkins, Director of Innovation, Medical Research Council
  • In-Depth Focus: Assays
  • Research Area: Alzheimer’s Disease – Calcilytics as potential novel therapeutic treatments to halt Alzheimer’s disease
    Anna Chiarini, Ubaldo Armato and Ilaria Dal Prà, University of Verona
  • In-Depth Focus: Imaging
  • Stem Cells: EUTCD-Grade lines – an innovative approach to creating and supplying clinical hESC lines
    Glyn Stacey, UK Stem Cell Bank
  • Flow Cytometry: accelerating neuroscience research
    Pushpanathan Muthuirulan, National Institute of Health
  • In-Depth Focus: NGS


The digital version of issue #3 2017 is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here